Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSP-CAR19M CD19-directed CAR-T cells in relapsed/refractory B-cell non-Hodgkin lymphoma
2024-519790-19-00Phase 2Authorised
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Jan 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HSP-CAR19M in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma (FL), sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoints: Primary - Safety of HSP-CAR19M infusion and Primary (expansion phase) - Safety and efficacy of HSP-CAR19M administration. Planned start Jan 2025; status: authorised.
02
Drugs
HSP-CAR19M
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2024-519790-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519790-19-00.